Johnson & Johnson announced on Thursday that the first clinical trials of a human coronavirus vaccine candidate have been launched in the United States and Belgium.
MODERNA STARTED TESTING OF PHASE 3 VACCINE
“We are pleased to see these preclinical data as they show that our candidate for the SARS-CoV-2 vaccine developed a strong antibody response and provided protection in a single dose,” said Paul Stoffels, the company’s chief scientific officer. statement. “The results give us confidence as we develop vaccines and products in parallel, initiating a Phase 1/ 2a trial in July, intending to move to a Phase 3 study in September.”
|Certainly||Security||The last one||Change||Replace%|
|JNJ||JOHNSONAS and JOHNSONAS||146.54||-0.29||-0.20 percent.|
Johnson & Johnson’s trials will include a “significant” representation of color communities and the elderly who have been disproportionately affected by the virus, the company said.
The pharmaceutical giant now has good news after the second-quarter decline in profits. The company has seen declining demand for both beauty products and medical devices, which has affected its substance.
Click here to read more about FOX BUSINESS
Twenty coronavirus vaccines are available in clinical trials, according to research by the Milken Institute. Moderna, based in the USA, is one of the most vaccinated companies.
GET THE FOX BUSINESS BY CLICKING HERE